Abstract
Neurological complications are an increasingly recognized complication of the use of the immune checkpoint inhibitors in the treatment of solid tumors. Ipilimumab is a monoclonal antibody against cytotoxic T-lymphocyte antigen-4, an immune checkpoint inhibitor that suppresses T-cell effector function. The clinical spectrum of ipilimumab-associated neurological complications and optimum treatment approach is not established. We describe our institution's experience with ipilimumab and illustrate 2 cases of presumed autoimmune neurological phenomenon resulting from its use.
Original language | English (US) |
---|---|
Pages (from-to) | 98-99 |
Number of pages | 2 |
Journal | Neurologist |
Volume | 23 |
Issue number | 3 |
DOIs | |
State | Published - 2018 |
Keywords
- CTLA-4
- checkpoint inhibitors
- general neurology
- ipilimumab
- neurological complications
ASJC Scopus subject areas
- Clinical Neurology